The latest action by industry on COVID-19
A rundown of the latest updates emerging from industry in response to the developing coronavirus pandemic.
With the situation changing each day, we provide an update on the significant recent actions that have emerged from pharmaceutical companies and regulatory agencies to combat the novel coronavirus.
Protecting the supply chain
- EMA states that there are currently no shortages, though this could change
- US FDA announces first drug shortage
- Sanofi states that it expects no shortages
- India stops export certain APIs and formulation, leading to fears within European industry over supply
Regulatory reaction
- US FDA and EMA provide updated timelines of events
- US FDA cancels foreign inspections, followed by domestic inspections
- Pressures on chloroquine supply lead to US FDA lifting import alert
Industry response
- Companies note potential financial impact
- Price hikes of certain products observed
- Calls for unified industry approach
- US and EU industry provide immediate response
- Partners come together to develop treatment
Potential treatments
- First vaccine enters trial
- Industry donates potential treatment doses
- Existing treatments enter the clinic
Industry events
